Announcement of serious abnormal fluctuations in stock trading of Beijing Rejing Biotechnology Co., Ltd.
Securities code: 688068 Securities abbreviation: Rejing Biotechnology Announcement number: 2026-033
Beijing Rejing Biotechnology Co., Ltd.
Announcement of serious abnormal fluctuations in stock trading
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.
Important content reminder:
The cumulative deviation of the closing price decline of Beijing Rejing Biotechnology Co., Ltd. (hereinafter referred to as the "Company") within 30 consecutive trading days (from April 2, 2026 to May 19, 2026) reached 70%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules" and "Shanghai Stock Exchange Science and Technology Innovation Board Real-time Monitoring Rules for Abnormal Stock Trading", it is a serious abnormal fluctuation in stock trading.
After the company’s self-examination and a letter to inquire about the controlling shareholders and actual controllers, as of the disclosure date of this announcement, the company has no major matters that should be disclosed but have not been disclosed. The company’s current internal production and operation activities are normal and no major changes have occurred.
Risk of profit loss: According to the first quarter report of 2026 disclosed by the company, the operating income in the first quarter of 2026 was 116.026 million yuan, an increase of 24.44% compared with the same period last year; however, due to the large investment in R&D and marketing promotion expenses, the net profit attributable to shareholders of the listed company was -68.0594 million yuan, an expansion compared with the loss in the same period last year; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was - 76.3407 million yuan, an increase in losses compared with the same period last year.
The company specifically reminds investors to pay attention to investment risks, make rational decisions, and invest prudently.
1. Specific circumstances of abnormal stock trading fluctuations
During the 30 consecutive trading days of the company's stock trading (from April 2, 2026 to May 19, 2026), the cumulative deviation of the closing price decline reached 70%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules" and "Shanghai Stock Exchange Science and Technology Innovation Board Real-time Monitoring Rules for Abnormal Stock Trading", it is a case of serious abnormal fluctuations in stock trading.
2. Relevant situations that the company pays attention to and verifies
In view of the abnormal fluctuations in the company's stock trading, after the company self-examined and issued a letter to confirm the company's controlling shareholders and actual controllers, the relevant situation is explained as follows:
(1) Daily operations
According to the company's self-examination, the company's current production and operation activities are all normal. In the first quarter of 2026, it achieved operating income of 116.026 million yuan, an increase of 24.44% compared with the same period last year; there have been no major adjustments to the market environment and industry policies, there have been no significant fluctuations in production costs and sales, and the internal production and operation order is normal.
(2) Progress of innovative drug research and development
According to the company's self-examination, in the field of innovative biological drugs, the company continues to expand the company's strategic business, and actively deploys cutting-edge innovative technologies in the field of biopharmaceuticals such as antibody drugs and nucleic acid drugs through its holding company Sunny Pharmaceuticals, joint-stock companies Zhiyuan Biotech and Yaojing Gene. It has also formed the world's first myocardial infarction emergency antibody drug SGC001, which is in phase II clinical research, SGT003, which has submitted a clinical trial application, Chiyuan Biotech's AD treatment antibody drug AA001, which is in phase Ib clinical research, and the first wave of results of Yaojing Gene's extrahepatic targeted small nucleic acid drug delivery platform.
Among them: SGC001, the myocardial infarction emergency antibody drug of Sunnyview Pharmaceuticals, has completed the enrollment and administration of the first subject in the Phase II clinical study on March 9, 2026, and held a SGC001 Phase II clinical investigators meeting in Beijing on April 25, 2026. More than 20 participating research centers across the country participated in the meeting. The current phase II clinical study of the project is proceeding as planned; SGC001 Phase II clinical studies for anticipated indications of severe pancreatitis will be submitted to CDE in the near future; SGT003 injection, a new bispecific antibody drug candidate developed by Sunview Pharmaceuticals based on its self-constructed NexTreg™ technology platform, has received an "Acceptance Notice" from the National Medical Products Administration in early April 2026; other pipelines under development are progressing normally.
Zhiyuan Biotech’s AD treatment antibody drug AA001, which is in Phase Ib clinical research, has completed the enrollment and administration of the first Alzheimer’s disease subject in early March 2026. The Phase Ib clinical research is currently underway as planned.
(3) Major events
After self-examination by the company and verification by letter from the controlling shareholder and actual controller: as of the disclosure date of this announcement, except for the information that has been publicly disclosed in designated media, there are no major events that affect abnormal fluctuations in the company’s stock trading price, including but not limited to planning for mergers and acquisitions, share issuance, debt restructuring, business restructuring, asset divestitures, asset injections and other major events.
(4) Media reports, market rumors, and hot concepts
The company has not found any media reports or market rumors that may have a greater impact on the company's stock trading price, nor has it found any other major events that may have a greater impact on the company's stock price.
(5) Other price-sensitive information
After verification, the company found no other major events that may have a greater impact on the company's stock price. The company's directors, senior managers, controlling shareholders, and actual controllers did not buy or sell the company's stocks during the company's abnormal stock trading period.
3. Statement of the Board of Directors and Commitments of Related Parties
The company's board of directors confirms that as of the date of this announcement, the company has no matters that should be disclosed but have not been disclosed in accordance with the "Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules" and other relevant regulations, or plans and intentions related to such matters. The board of directors has also not been informed of any undisclosed information that should be disclosed in accordance with the "Shanghai Stock Exchange's Science and Technology Innovation Board's Stock Listing Rules" and other relevant regulations that may have a greater impact on the company's stock trading price.
4. Related risk warnings
(1) The cumulative deviation of the closing price decline of the company’s stock within 30 consecutive trading days (from April 2, 2026 to May 19, 2026) reaches 70%. The company specifically reminds investors that the company's stock price has fallen significantly in the short term, and there may be risks of price fluctuations. Investors are advised to pay attention to investment risks, make rational decisions, and invest prudently.
(2) Risk of profit loss: According to the first quarter report of 2026 disclosed by the company, operating income in the first quarter of 2026 was 116.026 million yuan, an increase of 24.44% compared with the same period last year; however, due to large investment in R&D and marketing promotion fees, the net profit attributable to shareholders of the listed company was -6,805.94 million, the loss expanded compared with the same period last year; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -76.3407 million yuan, the loss expanded compared with the same period last year.
(3) The company will truthfully, accurately, timely, completely and fairly disclose material information that may affect the company's stock price to investors in accordance with the requirements of the "Company Law of the People's Republic of China", the Securities Law of the People's Republic of China and other relevant laws and regulations, so that investors can make investment judgments. Due to objective conditions, the company cannot grasp the causes and trends of stock market changes. The company reminds investors to pay attention to stock price fluctuations and possible risks involved in the stock market in the future.
(4) The company solemnly reminds investors that "Shanghai Securities News" and "Securities Daily" are the company's designated information disclosure newspapers, and the Shanghai Stock Exchange website (www.sse.com.cn) is the company's designated information disclosure website. All company information is subject to information published in the above designated media. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Beijing Rejing Biotechnology Co., Ltd.
May 20, 2026